Vigabatrin For Solution
Product Images NDC 60219-1425

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Vigabatrin (NDC 60219-1425). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Ny Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1 (Vigabatrin For Oral Solution Usp 500 mg 1)

1 (Vigabatrin For Oral Solution Usp 500 mg 1)
FDA Label Image

7 (Vigabatrin For Oral Solution Usp 500 mg 10)

7 (Vigabatrin For Oral Solution Usp 500 mg 10)
FDA Label Image

8 (Vigabatrin For Oral Solution Usp 500 mg 11)

8 (Vigabatrin For Oral Solution Usp 500 mg 11)
FDA Label Image

9 (Vigabatrin For Oral Solution Usp 500 mg 12)

9 (Vigabatrin For Oral Solution Usp 500 mg 12)
FDA Label Image

10 (Vigabatrin For Oral Solution Usp 500 mg 13)

10 (Vigabatrin For Oral Solution Usp 500 mg 13)
FDA Label Image

11 (Vigabatrin For Oral Solution Usp 500 mg 14)

11 (Vigabatrin For Oral Solution Usp 500 mg 14)
FDA Label Image

12 (Vigabatrin For Oral Solution Usp 500 mg 15)

12 (Vigabatrin For Oral Solution Usp 500 mg 15)
FDA Label Image

1 (Vigabatrin For Oral Solution Usp 500 mg 16)

1 (Vigabatrin For Oral Solution Usp 500 mg 16)
FDA Label Image

2 (Vigabatrin For Oral Solution Usp 500 mg 17)

2 (Vigabatrin For Oral Solution Usp 500 mg 17)
FDA Label Image

1 (Vigabatrin For Oral Solution Usp 500 mg 2)

1 (Vigabatrin For Oral Solution Usp 500 mg 2)
This text seems to be evaluating the reduction in seizure frequency among a group of patients. It provides percentages representing the reduction or improvement in seizure frequency, with values of 75%, 25%, and -25%. The text also includes a figure labeled as "Figure 1" that shows the percent reduction from baseline in seizure frequency. Additionally, there is a reference to "Improvement" and "No Change" in relation to the seizure frequency. The text seems to contain incomplete information and lacks further context to provide a more detailed description.*
FDA Label Image

2 (Vigabatrin For Oral Solution Usp 500 mg 3)

2 (Vigabatrin For Oral Solution Usp 500 mg 3)
FDA Label Image

1 (Vigabatrin For Oral Solution Usp 500 mg 4)

1 (Vigabatrin For Oral Solution Usp 500 mg 4)
FDA Label Image

2 (Vigabatrin For Oral Solution Usp 500 mg 5)

2 (Vigabatrin For Oral Solution Usp 500 mg 5)
FDA Label Image

3 (Vigabatrin For Oral Solution Usp 500 mg 6)

3 (Vigabatrin For Oral Solution Usp 500 mg 6)
FDA Label Image

4 (Vigabatrin For Oral Solution Usp 500 mg 7)

4 (Vigabatrin For Oral Solution Usp 500 mg 7)
FDA Label Image

5 (Vigabatrin For Oral Solution Usp 500 mg 8)

5 (Vigabatrin For Oral Solution Usp 500 mg 8)
FDA Label Image

6 (Vigabatrin For Oral Solution Usp 500 mg 9)

6 (Vigabatrin For Oral Solution Usp 500 mg 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.